Our approach provides the only protein-based means to target the RNA in cancer cells. Our EVade™ ribonucleases have selectivity for cancer cells due to their affinity for the anionic glycans that are overexpressed in cancer. Our lead candidate, called QBI-139, has a strong therapeutic window against a variety of in vivo solid tumors in xenograft models including: colon, non-small cell lung, ovarian, pancreatic and prostate cancer. A first in human, dose escalation Phase I trial in patients with solid tumors showed that QBI-139 has a favorable safety profile, without the common side effects of chemotherapies (e.g. myelosuppression). At the higher dose levels, QBI-139 showed an increased rate of stable disease as well as changes in serum markers for two prostate cancer patients.
See where Quintessence Biosciences is presenting in the coming months.
American Association for Cancer Research Annual Meeting
18-22 April 2015
Quintessence Biosciences (QuintBio) will be meeting with collaborators and future partners at the AACR conference in Philadelphia.